PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

BACKGROUND: Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases. Chemotherapy reduces tumor recurrence after resection, but debilitating toxicities render a large percentage of patients ineligible. Recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharjee, Sayani, Sullivan, Matthew J., Wynn, Rebecca R., Demagall, Alex, Hendrix, Andrew S., Sindhwani, Puneet, Petros, Firas G., Nadiminty, Nagalakshmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944004/
https://www.ncbi.nlm.nih.gov/pubmed/35321693
http://dx.doi.org/10.1186/s12885-022-09376-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944004/
https://www.ncbi.nlm.nih.gov/pubmed/35321693
http://dx.doi.org/10.1186/s12885-022-09376-9

Ejemplares similares